NNutrition Read More ‘Miracle’ supplement recalled nationwide over death, diarrhea risks14 February 2026 A supplement described as from a “miracle tree” by a nutritional therapist has been recalled because of possible…
MMedication Read More Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP13 February 2026 Disc Medicine Inc FDA acknowledged that AURORA and BEACON provided sufficient evidence that bitopertin significantly lowers PPIX and…
MMedication Read More Hims & Hers compounder received FDA warning letter| STAT10 February 2026 The Food and Drug Administration late last year issued a warning letter to MedisourceRx, a compounding pharmacy owned…
GGermany Read More Germany Bans Amazon from Price Controls6 February 2026 This Week’s Regulatory Updates Germany bans Amazon price caps: The Bundeskartellamt demands Amazon halt anti-competitive pricing and repay…
MMedication Read More Marty Makary addresses staff concerns over drug voucher program4 February 2026 WASHINGTON — At an employee town hall on Tuesday, Food and Drug Administration leaders tried to quell staff…
MMedication Read More Will 2026 FDA Decisions on Afrezza and FUROSCIX Redefine MannKind’s (MNKD) Narrative22 January 2026 Earlier in January, MannKind Corporation outlined upcoming 2026 regulatory milestones, including FDA decisions on Afrezza label updates, a…
MMedication Read More FDA Goon Delivers Wild Take on Prescription Drug Safety18 January 2026 FDA commissioner Marty Makary said it would be “magical” for consumers to see prescription drugs on pharmacy shelves…
MMedication Read More NRx submits 70,000-patient ketamine data to US FDA14 January 2026 NRx Pharmaceuticals (Nasdaq: NRXP) will submit real-world evidence from over 70,000 patients treated with intravenous ketamine…
MMedication Read More Tylenol, Advil, Purina, Haribo face urgent FDA recall5 January 2026 While a car recall is one notice I never ignore, I can’t ever remember throwing out a single…
MMedication Read More FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)29 December 2025 PLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ — INOVIO (NASDAQ: INO), a biotechnology company focused on developing and…